Clinical Features and Outcome of Inflammatory Breast Cancer in Moroccan Population: Experience of Oncology Department of National Institute of Rabat

Imane Ouziane; Bensouda Y; HMrabti MD; Elomrani F MD; Elismaili N MD

Authors

Imane Ouziane
Bensouda Y
HMrabti MD
Elomrani F MD
Elismaili N MD

Keywords:

inflammatory breast cancer, neoadjuvant chemotherapy, pathological complete response, moroccan, hormonal receptor, her2neu

Abstract

Abstract not found

Downloads

How to Cite

Clinical Features and Outcome of Inflammatory Breast Cancer in Moroccan Population: Experience of Oncology Department of National Institute of Rabat. (2015). Global Journal of Medical Research, 15(23), 1-8. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

Bouzaiene Boussen H, Dhiab Ben Hassouna J, Benna Khomsi F, clinical .Cancer (2010) Inflammatory breast cancer in Tunisia: epidemiological and clinical trends. 116(11 Suppl), 2730-5.

Mourali N, Muenz LR, Tabbane F, Belhassen S, Bahi J (1980) Epidemiologic features of rapidly progressing breast cancer in Tunisia. 46(12), 27412746. https://doi.org/10.1002/1097-0142(19801215)46:12

Shine Chang, Sheryl Parker, Tuan Pham, Aman Buzdar, Stephen Hursting (1998) Inflammatory breast carcinoma incidence and survival. 82(12), 2366-2372.

Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst. 97(13), 966-975.

Glenn Lawson JS, Ye Salmons B, Moody Heng B (2010) Mouse Mammary Tumor Virus-like Sequences in Human Breast Cancer. 70(9), 3576-3585. https://doi.org/10.1158/0008-5472.can-09-4160

S. Singletary, Massimo Cristofanilli (2008) Defining the Clinical Diagnosis of Inflammatory Breast Cancer seminars in oncology. 35(1), 7-10. https://doi.org/10.1053/j.seminoncol.2007.11.010

William Anderson, Catherine Schairer, Bingshu Chen, Kenneth Hance, Paul Levine (2005) Anderson, Catherine Schairer, Bingshu E Chen, Kenneth W Hance, Paul H Levine Epidemiology of inflammatory breast cancer Breast Disease Breast Dis. 22, 9-23.

(2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. 22(3), 515-523.

Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G (1989) Cell kinetics and hormonal receptor status in inflammatory breast carcinoma: Comparison with locally advanced disease Cancer. 64(9).

William Anderson, Kenneth Chu, Shine Chang (2003) Inflammatory Breast Carcinoma and Noninflammatory Locally Advanced Breast Carcinoma: Distinct Clinicopathologic Entities?. 21(12), 2254-2259. https://doi.org/10.1200/jco.2003.07.082

(2008) Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry. 8, 28.

Chaher N, Arias-Pulido H, Terki N, Qualls C, Bouzid K, Verschraegen C (2012) Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients Breast Cancer Res Treat. 131(2), 437-444.

Gabillot Guerin M, JP MC Mathieu, N. M Spielmann (1989) Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance International Journal of Cancer Volume 43. 43(2), 201-208. https://doi.org/10.1002/ijc.2910430205

Gonzalez-AnguloAM, SneigeN, Buzdar AU, Valero V, M. Cristofallini (2004) p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer. 10, 6215.

Kleer CG, Van KL, Braun T, Merajver SD (2001) Persistent E-Cadherin Expression in Inflammatory Breast Cancer. 14(5), 458-464.

PB CG Colpaert, A. I Benoy, F. Van Roy (2003) Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression British Journal of Cancer 2003. 88(5), 718-725. https://doi.org/10.1038/sj.bjc.6600807

L. Kenneth, Seena van Golen, Davies, Fen Zhi, Yunfang Wu, Corazon Wang (1999) van Golen, Seena Davies, Zhi Fen Wu, YunFang Wang, Corazon D Bucana, Holly Root, : A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory Breast cancer), and Rhoc GTPase correlate with the inflammatory breast cancer phenotype. 5(9), 2511-2519.

Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA Inflammatory Breast Cancer: What We Know and What We Need to Learn. 17(7), 891-899.

T. Naoto, Aman Ueno, Sonja Buzdar, Frederick Singletary, Marsha Ames, McNeese (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. 40(4), 321-329.

Massimo Cristofanilli, Ana Gonzalez-Angulo, Aman Buzdar, Shu-Wan Kau, Debbie Frye, Gabriel Hortobagyi (2004) Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M D Anderson Cancer Center experience Clin Breast Cancer. 4(6), 415-419. https://doi.org/10.3816/cbc.2004.n.004

Eiermann Gianni L, Manikhas Semiglazov V, Lluch A, locally cancer, The trial (2010) Lancet. 375(9712), 377-384.

Bernard Chevallier, Bernard Asselain, Antoine Kunlin, Corinne Veyret, Philippe Bastit, Yvon Graic (1987) Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. 60(4), 897-902. https://doi.org/10.1002/1097-0142(19870815)60:4

I. Faneyte, J. Schrama, J. Peterse, P. Remijnse, S. Rodenhuis, M. van de Vijver (2003) Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ.Breast cancer response to neoadjuvant chemotherapy : predictive markers and relation with outcome. 88, 406-412.

J. Eur (1992) E Belembaogo, V Feillel, P Chollet, H Cure, P Verrelle, F Kwiatkowski, Neoadjuvant chemotherapy in 126 operable breast cancers. (4-5), 896-900.

Ames Smith TL, Dhingra Hunt KK (1999) Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. 17, 460-469.

Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S (2010) Inflammatory breast cancer: the disease, the biology, the treatment, CA Cancer J Clin. 60(6), 351-375.

C. Colpaert, P. Vermeulen, L. Dirix, Van Marck, E. (2003) Microvessel density, expression of oestrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast Cancer Clin Cancer Res. 9(10 Pt 1), 3815-3816.

Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J (2012) Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study Lancet Oncol. 13(4), 375-384.

S. Rabiya, Tuma (2012) ALK gene amplified in most inflammatory breast cancers. 104(2), 87-88.